Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase (EC 2.4.2.21), also known as CobT, is an enzyme that catalyzes the phosphoribosyltransfer reaction essential for the biosynthesis of cobalamin (vitamin B12) in bacteria. It converts beta-nicotinate D-ribonucleotide and 5,6-dimethylbenzimidazole into alpha-ribazole-5'-phosphate, a key intermediate for assembling the nucleotide loop of cobalamin. CobT is a glycosyltransferase of the pentosyltransferase family and plays a central role in the anaerobic pathway of vitamin B12 production. Structurally, CobT is a dimer with each subunit featuring a Rossmann fold and a three-helix bundle domain. The enzyme’s active site forms a hydrophobic pocket accommodating the substrate 5,6-dimethylbenzimidazole, and it undergoes a disorder-to-order transition upon substrate binding. It is distinct in structure from other phosphoribosyltransferases, and its function is crucial for bacterial metabolism but not directly linked to human enzymes or diseases[1][2][4][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase (CobT).